Biotech Daily Dose


pharma-021618_17jan19.jpg Today's Daily Dose brings you news about FDA thumbs down on Immunomedics' breast cancer drug; FDA panel vote on Sanofi/Lexicon's diabetes drug; progress in Zymeworks/ Lilly collaboration; and encouraging data from Zafgen's diabetes trial.

pharma-021218_17jan19.jpg Today's Daily Dose brings you news about Alder Biopharma's after-hours stock movement; Mirati's stock offering; FDA panel recommendation of Amgen/UCB's osteoporosis drug Evenity; and Pain Therapeutics' grant award.

pharma-022818_15jan19.jpg Today's Daily Dose brings you news about the approval of the world's first device for treatment of premature babies and newborns with an opening in their hearts; the impact of the U.S. government shutdown on Aimmune Therapeutics; Array's BEACON CRC trial results; and Exelixis' expanded FDA approval for Cabometyx tablets.

happysadinvestors-jan11.jpg Biotech stocks are mostly driven by clinical trial results and regulatory decisions. Listed below are some of the companies that await FDA decision or are expected to report their clinical trial results *this month (if the companies stick to their timeline).

phama-daily-080218_09jan19.jpg Today's Daily Dose brings you news about preliminary financial results of Globus Medical, Conformis, and GenMark Diagnostics; approval of Amgen's Evenity in Japan; Genmab's achievement of a milestone payment related to Darzalex; and executive changes in Abeona.

pharma-020118_04jan19.jpg Today's Daily Dose brings you news about this year's first, and one of the biggest pharmaceuticals deals; BioXcel Therapeutics' Alzheimer's study results; CAS Medical's preliminary unaudited Q4 sales results; Catabasis Pharma's update on DMD trial; Marker Therapeutics' pipeline progress; and Novavax' phase II clinical trial results of NanoFlu.

pharma-021518_03jan19.jpg Today's Daily Dose brings you news about disappointing trial results of Aevi Genomic; progress in Allena's phase III program of Reloxaliase; FDA approval of Bristol-Myers' blockbuster Sprycel for another indication; and update on Flexion's phase III trial of ZILRETTA in patients with hip osteoarthritis.

fleurstat-dec20.jpg Shares of Australian biotech company Starpharma Holdings Ltd. (SPHRY.OB) slipped to a new 52-week low on Thursday, following disappointing regulatory news related to VivaGel BV in the U.S.

flexion-dec26.jpg Clinical trials are major catalysts for biotech/pharma companies as positive study data can boost their stock price while unfavorable results can send the stocks plummeting.

Follow RTT